查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108226

冷凍組織樣本市場分析及預測（至2035年）：類型、產品、服務、技術、組件、應用、過程、最終用戶、解決方案、階段

Frozen Tissues Samples Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User, Solutions, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球冷凍組織樣本市場預計將從2025年的44億美元成長到2035年的83億美元，CAGR為6.4%。在全球生物樣本庫、專業生物樣本供應商、學術機構和合約研究組織（CRO）的推動下，冷凍組織樣本市場正經歷適度的整合，這些機構為轉化研究、精準醫療和藥物研發提供高品質的冷凍保存組織樣本。人體組織樣本佔據了最大的市場需求佔有率，尤其在腫瘤學、遺傳學研究和生物標記發現應用領域需求旺盛。冷凍組織塊和切片在基因組學、蛋白質組學和新一代定序工作流程中的應用也在不斷成長。對自動化生物銀行基礎設施、數位化樣本管理和標準化冷凍保存技術的策略性投資，持續提升樣本品質、可追溯性和長期儲存效率。例如，2025年 1月，英國生物銀行啟動了全球最大的人類蛋白質體學研究，利用了 60萬個生物樣本，加速了生物標記的發現和精準醫學研究，並顯著增加了對高品質保存生物樣本的需求。

依類型分析市場，2025年人體組織樣本細分市場將引領冷凍組織樣本市場的發展。這主要歸功於其在生物醫學研究、臨床診斷、轉化醫學和藥物研發領域的廣泛應用。人體組織樣本對於闡明疾病機制、發現生物標記、精準醫療以及檢驗腫瘤、神經病學、心血管疾病和罕見疾病等領域的治療標靶非常重要。生物銀行基礎設施投資的增加、臨床研究活動的活性化、基因組學和蛋白質組學研究的拓展以及對高品質生物檢體日益成長的需求，都在推動這一細分市場的成長。此外，醫院、研究機構和生物製藥公司之間合作的加強也持續促進了冷凍保存的人體組織樣本在全球範圍內的廣泛應用。

市場區隔
類型 人體組織樣本、動物組織樣本、植物組織樣本、其他
產品 冷凍組織塊、冷凍組織切片、其他
服務 組織採集、組織保存、組織分配、其他
技術 冷凍保存、快速冷凍、玻璃化冷凍、其他
組件 儲存設備、運輸設備、其他
用途 癌症研究、基因研究、藥物研發、移植研究、其他
過程 樣品製備、樣品儲存、樣品分析、其他
最終用戶 生物樣本庫、研究機構、製藥公司、醫院、學術機構、其他
解決方案 樣品管理軟體、資料分析工具、其他
階段 臨床前、臨床、臨床後、其他

依應用領域分類，癌症研究領域預計在預測期內實現最快成長。這主要得益於全球癌症發生率的上升、腫瘤臨床檢測的增加以及精準腫瘤學研究的拓展。冷凍組織樣本對於腫瘤分析、生物標記鑑定、腫瘤免疫學研究和標靶治療開發非常重要，因為它們能夠維持DNA、RNA和蛋白質的完整性。新一代定序、空間生物學和分子診斷技術的日益普及加速對高品質冷凍生物檢體的需求。此外，對癌症生物樣本庫、政府資助的研究計畫以及製藥公司著重個人化癌症治療的研發投入的增加，預計將進一步推動癌症研究領域的快速成長。

區域概覽

到2025年，北美將佔據冷凍組織樣本市場最大的佔有率，這得益於其完善的生物銀行基礎設施、先進的生命科學研究生態系統以及強大的製藥和生物技術公司實力。美國憑藉在精準醫療、癌症研究、基因組學和轉化醫學領域的大規模投資，以及大規模的生物樣本庫網路和政府資助的生物醫學研究計畫，在區域市場中佔據主導地位。加拿大也透過擴大國家生物銀行舉措、增加臨床研究活動以及加強學術機構、醫療服務提供者和生物技術公司之間的合作，做出了重要貢獻，進一步增強了該地區對高品質冷凍組織樣本的需求。

預計亞太地區將在預測期內實現最快成長，這主要得益於生物醫學研究的拓展、基因組學和精準醫療領域投資的增加，以及新興經濟體生物銀行基礎設施的快速發展。中國、日本、印度和韓國在區域市場中處於領先地位，這得益於它們在製藥領域的研發投入不斷增加、臨床試驗日益增多、癌症研究活動活性化，以及政府對生命科學研究的大力支持。合約研究組織（CRO）的日益普及、醫療基礎設施的不斷完善，以及先進分子診斷和新一代定序技術的廣泛應用，預計將進一步推動全部區域對冷凍組織樣本的需求成長。

主要趨勢和促進因素

精準醫療和轉化研究的傳播

冷凍組織樣本市場正呈現顯著趨勢：精準醫療、轉化研究和分子診斷領域對冷凍生物檢體的需求日益成長。高品質的冷凍組織樣本對於基因組學、轉錄組學、生物標記發現和標靶治療研發非常重要，因為它們能夠維持DNA、RNA和蛋白質的完整性。新一代定序、空間生物學和多體學技術的日益普及推動了對標準化生物樣本的需求。此外，生物樣本庫網路的擴展以及研究機構、醫院和製藥公司之間合作的加強，也增加了可用於高級生物醫學研究的詳細、特徵明確的組織樣本的可用性。

增加對生物銀行基礎設施和生命科學研究的投資。

冷凍組織樣本市場的主要驅動力是全球生物銀行基礎設施、生物醫學研究和藥物研發計畫的投資不斷增加。各國政府、學術機構、製藥公司和生物技術公司日益擴大組織庫，以支持腫瘤學研究、精準醫療、再生醫學和臨床試驗。慢性病盛行率的上升、對個人化療法需求的成長以及製藥領域研發活動的不斷擴大，持續推動對高品質冷凍組織樣本的需求。冷凍保存技術、自動化儲存系統和數位化生物樣本庫管理解決方案的不斷進步，將進一步促進市場的長期成長，同時提高生物樣本的品質和可用性。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機會
  • 市場限制因素
  • 年複合成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 人體組織樣本
    • 動物組織樣本
    • 植物組織樣本
    • 其他
  • 市場規模及預測：依產品分類
    • 冷凍組織塊
    • 冰凍組織切片
    • 其他
  • 市場規模及預測：依服務分類
    • 組織採集
    • 組織保存
    • 組織分佈
    • 其他
  • 市場規模及預測：依技術分類
    • 冷凍保存
    • 快速冷凍
    • 玻璃化
    • 其他
  • 市場規模及預測：依應用領域分類
    • 癌症研究
    • 遺傳學研究
    • 藥物研發
    • 移植研究
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 生物樣本庫
    • 研究所
    • 製藥公司
    • 醫院
    • 學術機構
    • 其他
  • 市場規模及預測：依製程分類
    • 樣品製備
    • 樣品儲存
    • 樣品分析
    • 其他
  • 市場規模及預測：依組件分類
    • 儲存裝置
    • 運輸設備
    • 其他
  • 市場規模及預測：依解決方案分類
    • 樣品管理軟體
    • 資料分析工具
    • 其他
  • 市場規模及預測：依階段分類
    • 臨床前
    • 臨床
    • 臨床後
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要公司的策略

第8章 公司簡介

  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • QIAGEN
  • Merck KGaA
  • Roche Diagnostics
  • Agilent Technologies
  • PerkinElmer
  • Becton Dickinson
  • Illumina
  • Leica Biosystems
  • Miltenyi BIoTec
  • Takara Bio
  • Promega Corporation
  • Abcam
  • Cell Signaling Technology
  • Bio-Techne
  • GenScript BIoTech
  • Sakura Finetek
  • VWR International
  • Avantor

第9章 關於我們

簡介目錄
Product Code: GIS10495

The global Frozen Tissues Samples Market is projected to grow from $4.4 billion in 2025 to $8.3 billion by 2035, at a compound annual growth rate (CAGR) of 6.4%. The Frozen Tissue Samples Market is moderately consolidated, supported by global biobanks, specialized biospecimen providers, academic institutions, and contract research organizations supplying high-quality cryopreserved tissue samples for translational research, precision medicine, and drug discovery. Human tissue samples account for the largest share of market demand, particularly for oncology, genetic research, and biomarker discovery applications. The market is witnessing increasing utilization of frozen tissue blocks and sections for genomics, proteomics, and next-generation sequencing workflows. Strategic investments in automated biobanking infrastructure, digital sample management, and standardized cryopreservation technologies continue to improve sample quality, traceability, and long-term storage efficiency. For instance, in January 2025, UK Biobank launched the world's largest human proteomics study, utilizing 600,000 biological samples to accelerate biomarker discovery and precision medicine research, significantly strengthening demand for high-quality preserved biospecimens.

Based on Type, the Human Tissue Samples segment dominated the Frozen Tissue Samples Market in 2025 due to its extensive use in biomedical research, clinical diagnostics, translational medicine, and pharmaceutical development. Human tissue samples are essential for studying disease mechanisms, biomarker discovery, precision medicine, and therapeutic target validation across oncology, neurology, cardiovascular disorders, and rare diseases. Growing investments in biobanking infrastructure, increasing clinical research activities, expanding genomic and proteomic studies, and rising demand for high-quality biospecimens have strengthened segment growth. Additionally, increasing collaborations among hospitals, research institutes, and biopharmaceutical companies continue to support the widespread utilization of cryopreserved human tissue samples globally.

Market Segmentation
TypeHuman Tissue Samples, Animal Tissue Samples, Plant Tissue Samples, Others
ProductFrozen Tissue Blocks, Frozen Tissue Sections, Others
ServicesTissue Collection, Tissue Preservation, Tissue Distribution, Others
TechnologyCryopreservation, Flash Freezing, Vitrification, Others
ComponentStorage Equipment, Transport Equipment, Others
ApplicationCancer Research, Genetic Studies, Drug Development, Transplant Research, Others
ProcessSample Preparation, Sample Storage, Sample Analysis, Others
End UserBiobanks, Research Laboratories, Pharmaceutical Companies, Hospitals, Academic Institutions, Others
SolutionsSample Management Software, Data Analysis Tools, Others
StagePre-clinical, Clinical, Post-clinical, Others

Based on Application, the Cancer Research segment is projected to register the fastest growth during the forecast period, driven by increasing global cancer prevalence, rising oncology clinical trials, and expanding precision oncology research. Frozen tissue samples preserve DNA, RNA, and protein integrity, making them indispensable for tumor profiling, biomarker identification, immuno-oncology studies, and targeted therapy development. Growing adoption of next-generation sequencing, spatial biology, and molecular diagnostics is accelerating demand for high-quality frozen biospecimens. Furthermore, increasing investments in cancer biobanks, government-funded research programs, and pharmaceutical R&D focused on personalized cancer therapies are expected to further drive rapid growth of the cancer research segment.

Geographical Overview

North America accounted for the largest share of the Frozen Tissue Samples Market in 2025, supported by its well-established biobanking infrastructure, advanced life sciences research ecosystem, and strong presence of pharmaceutical and biotechnology companies. The United States dominates the regional market due to extensive investments in precision medicine, cancer research, genomics, and translational medicine, alongside large-scale biobank networks and government-funded biomedical research programs. Canada also contributes significantly through expanding national biobanking initiatives, increasing clinical research activities, and collaborations between academic institutions, healthcare providers, and biotechnology companies, further strengthening regional demand for high-quality frozen tissue samples.

Asia-Pacific is projected to register the fastest growth during the forecast period, driven by expanding biomedical research, increasing investments in genomics and precision medicine, and rapid development of biobanking infrastructure across emerging economies. China, Japan, India, and South Korea are leading regional markets due to growing pharmaceutical R&D, increasing clinical trials, rising cancer research activities, and supportive government funding for life sciences research. The expanding presence of contract research organizations (CROs), improving healthcare infrastructure, and rising adoption of advanced molecular diagnostics and next-generation sequencing technologies are expected to further accelerate demand for frozen tissue samples across the region.

Key Trends and Drivers

Increasing Adoption of Precision Medicine and Translational Research:

The Frozen Tissue Samples Market is witnessing a significant trend toward the growing use of frozen biospecimens in precision medicine, translational research, and molecular diagnostics. High-quality frozen tissue samples preserve DNA, RNA, and protein integrity, making them indispensable for genomics, transcriptomics, biomarker discovery, and targeted therapy development. Increasing adoption of next-generation sequencing, spatial biology, and multi-omics technologies is driving demand for standardized biospecimens. Furthermore, expanding biobank networks and collaborations among research institutes, hospitals, and pharmaceutical companies are strengthening the availability of well-characterized tissue samples for advanced biomedical research.

Growing Investments in Biobanking Infrastructure and Life Sciences Research:

The Frozen Tissue Samples Market is primarily driven by increasing global investments in biobanking infrastructure, biomedical research, and drug discovery programs. Governments, academic institutions, pharmaceutical companies, and biotechnology firms are expanding tissue repositories to support oncology research, precision medicine, regenerative medicine, and clinical trials. Rising prevalence of chronic diseases, increasing demand for personalized therapeutics, and growing pharmaceutical R&D activities continue to accelerate the need for high-quality frozen tissue samples. Continuous advancements in cryopreservation technologies, automated storage systems, and digital biobank management solutions are further supporting long-term market growth and improving biospecimen quality and accessibility.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Human Tissue Samples
    • 4.1.2 Animal Tissue Samples
    • 4.1.3 Plant Tissue Samples
    • 4.1.4 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Frozen Tissue Blocks
    • 4.2.2 Frozen Tissue Sections
    • 4.2.3 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Tissue Collection
    • 4.3.2 Tissue Preservation
    • 4.3.3 Tissue Distribution
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cryopreservation
    • 4.4.2 Flash Freezing
    • 4.4.3 Vitrification
    • 4.4.4 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Cancer Research
    • 4.5.2 Genetic Studies
    • 4.5.3 Drug Development
    • 4.5.4 Transplant Research
    • 4.5.5 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biobanks
    • 4.6.2 Research Laboratories
    • 4.6.3 Pharmaceutical Companies
    • 4.6.4 Hospitals
    • 4.6.5 Academic Institutions
    • 4.6.6 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Sample Preparation
    • 4.7.2 Sample Storage
    • 4.7.3 Sample Analysis
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Storage Equipment
    • 4.8.2 Transport Equipment
    • 4.8.3 Others
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Sample Management Software
    • 4.9.2 Data Analysis Tools
    • 4.9.3 Others
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Pre-clinical
    • 4.10.2 Clinical
    • 4.10.3 Post-clinical
    • 4.10.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Component
      • 5.2.1.9 Solutions
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Component
      • 5.2.2.9 Solutions
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Component
      • 5.2.3.9 Solutions
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Component
      • 5.3.1.9 Solutions
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Component
      • 5.3.2.9 Solutions
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Component
      • 5.3.3.9 Solutions
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Component
      • 5.4.1.9 Solutions
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Component
      • 5.4.2.9 Solutions
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Component
      • 5.4.3.9 Solutions
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Component
      • 5.4.4.9 Solutions
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Component
      • 5.4.5.9 Solutions
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Component
      • 5.4.6.9 Solutions
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Component
      • 5.4.7.9 Solutions
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Component
      • 5.5.1.9 Solutions
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Component
      • 5.5.2.9 Solutions
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Component
      • 5.5.3.9 Solutions
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Component
      • 5.5.4.9 Solutions
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Component
      • 5.5.5.9 Solutions
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Component
      • 5.5.6.9 Solutions
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Component
      • 5.6.1.9 Solutions
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Component
      • 5.6.2.9 Solutions
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Component
      • 5.6.3.9 Solutions
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Component
      • 5.6.4.9 Solutions
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Component
      • 5.6.5.9 Solutions
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Thermo Fisher Scientific
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Bio-Rad Laboratories
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 QIAGEN
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Merck KGaA
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Roche Diagnostics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Agilent Technologies
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 PerkinElmer
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Becton Dickinson
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Illumina
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Leica Biosystems
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Miltenyi Biotec
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Takara Bio
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Promega Corporation
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Abcam
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Cell Signaling Technology
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Bio-Techne
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 GenScript Biotech
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Sakura Finetek
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 VWR International
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Avantor
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us